Valiant Organics reported a consolidated net profit of ₹29.26 crore for Q1FY26, up 188% from ₹8.20 crore in Q1FY25. The surge was driven by a turnaround in its Pharma division, which returned to profitability, and significant earnings from associate companies. Consolidated revenue from operations grew 13% YoY to ₹231.54 crore, reflecting robust demand across both reportable segments. EBITDA rose to ₹416 crore from ₹248 crore, with operating margins expanding to 17.98% from 12.15% in the corresponding period last year.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026, based on the recommendation of the Audit Committee. The results were reviewed by statutory auditors Gokhale & Sathe under Standard on Review Engagement (SRE) 2410. The filing also disclosed the re-appointment of Sathiababu K. Kallada as Managing Director for a three-year term effective from May 24, 2027, subject to shareholder approval at the ensuing Annual General Meeting.

Financial performance highlights

Consolidated revenue from operations stood at ₹231.54 crore, compared to ₹204.41 crore in Q1FY25. Other income contributed ₹3.28 crore, bringing total income to ₹234.82 crore. Total expenses were contained at ₹205.27 crore, aided by a reduction in inventory levels that resulted in a negative change in inventories of ₹16.79 crore. Profit before tax reached ₹36.78 crore, up from ₹11.11 crore in the corresponding previous quarter.

Standalone net profit rose 188% to ₹21.82 crore from ₹7.58 crore in Q1FY25. Standalone revenue grew 13% to ₹231.54 crore. The company's basic earnings per share increased to ₹7.79 from ₹2.71 in the standalone results, while consolidated EPS jumped to ₹10.44 from ₹2.93.

Segment-wise analysis

The Specialty Chemicals division generated ₹175.74 crore in revenue, up 17% YoY, with segment results before interest and tax rising to ₹25.06 crore from ₹17.36 crore. The Pharma division saw revenue increase to ₹55.80 crore from ₹53.72 crore. Notably, the Pharma segment turned profitable, reporting segment results of ₹16.85 crore compared to a loss of ₹0.21 crore in Q1FY25. This operational improvement significantly boosted overall group profitability.

Corporate developments

The Board approved the re-appointment of Sathiababu K. Kallada as Managing Director for a term of three years, effective May 24, 2027, to May 23, 2030. He is not liable to retire by rotation. Additionally, the Board proposed shifting the registered office from Mulund, Mumbai, to Plot No. M-7, MIDC, Tarapur, Boisar, Palghar. This move involves a change in jurisdiction from the Registrar of Companies, Mumbai I, to Mumbai II. The corporate office remains at Vikhroli, Mumbai.

What the numbers show

The 188% jump in consolidated net profit is attributable to two factors: the operational turnaround in the Pharma division and a substantial share of profit from associates. While the Pharma segment contributed ₹16.85 crore directly, the share of profit from associates amounted to ₹7.23 crore, up from ₹0.62 crore in Q1FY25. This indicates that a significant portion of the bottom-line growth is driven by external investments rather than just core operating margins, although both segments showed positive momentum. The expansion in EBITDA margin to 17.98% from 12.15% underscores improved operational efficiency alongside the volume growth.

Valiant Organics Limited has decided not to proceed with a transaction regarding its cessation as a partner of Dhanvallabh Ventures LLP, leading to the cancellation of the related postal ballot process. The Board of Directors, acting on the recommendation of the Audit Committee and management submissions, resolved to halt the material related party transaction for the time being. Consequently, the electronic voting process initiated for this purpose has been withdrawn.

The postal ballot process, including the Electronic Voting Event Number (EVEN) 139390, stands cancelled with immediate effect. This decision was taken during a Board meeting held on June 18, 2026, which commenced at 4.25 P.M. (IST) and concluded at 5.05 P.M. (IST). The company stated that further updates will be provided as the Board deliberates on the matter.

Transaction Details

The filing pertains to a specific material related party transaction that required shareholder approval via postal ballot. The following table outlines the key details of the cancelled process:

The decision to withdraw the process was based on an evaluation of the facts and circumstances presented by the management. The company will notify the exchanges of any future developments regarding this transaction.